The potential impact of immunotherapy on cancer survival has been recently addressed by Emens et al. in a model showing that single-agent ipilimumab or PD-1/PD-L1 inhibitors and immunotherapy combinations targeting both CTLA-4 and PD-1 pathways are associated with long-term survival rates ranging from 10–30% and 50–60%, respectively [30]. This evidence concerns the gene PDCD1 and cancer.